During the last session, Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s traded shares were 1.08 million, with the beta value of the company hitting 2.07. At the end of the trading day, the stock’s price was $1.63, reflecting an intraday gain of 0.62% or $0.01. The 52-week high for the AUTL share is $6.48, that puts it down -297.55 from that peak though still a striking 4.29% gain since the share price plummeted to a 52-week low of $1.56. The company’s market capitalization is $433.78M, and the average intraday trading volume over the past 10 days was 1.3 million shares, and the average trade volume was 1.24 million shares over the past three months.
Autolus Therapeutics plc ADR (AUTL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AUTL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.26.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Autolus Therapeutics plc ADR (AUTL) registered a 0.62% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.62% in intraday trading to $1.63, hitting a weekly high. The stock’s 5-day price performance is -15.98%, and it has moved by -8.94% in 30 days. Based on these gigs, the overall price performance for the year is -74.21%. The short interest in Autolus Therapeutics plc ADR (NASDAQ:AUTL) is 9.13 million shares and it means that shorts have 7.04 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.6, which implies an increase of 78.55% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.6 and $7.6 respectively. As a result, AUTL is trading at a discount of -366.26% off the target high and -366.26% off the low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
In the rating firms’ projections, revenue will increase 214.45% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.42M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 5.34M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.36%. While earnings are projected to return -2.73% in 2025, the next five years will return 28.61% per annum.
AUTL Dividends
Autolus Therapeutics plc ADR is due to release its next quarterly earnings on 2025-Mar-19. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
Autolus Therapeutics plc ADR insiders own 18.09% of total outstanding shares while institutional holders control 86.12%, with the float percentage being 105.14%. SYNCONA PORTFOLIO LTD is the largest shareholder of the company, while 145.0 institutions own stock in it. As of 2024-06-30, the company held over 21.35 million shares (or 8.0243% of all shares), a total value of $74.29 million in shares.
The next largest institutional holding, with 20.49 million shares, is of BLACKSTONE INC.’s that is approximately 7.7006% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $71.29 million.
